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Introduction
Although all patients with chronic inflammatory condi-
tions are at risk for developing type AA amyloidosis, the
incidence varies widely between the different Autoin-
flammatory syndromes. The reported incidence is about
35% of patients with CAPS (cryopyrin-associated peri-
odic syndrome) which comprises familial cold auto-
inflammatory syndrome (FCAS), Muckle-Wells syn-
drome and CINCA (chronic infantile neurological cuta-
neous, articular inflammatory syndrome). CAPS is
associated with mutations in NLRP3/CIAS1 on chromo-
some 1q44, found only in about 50% of patients. Pre-
vious studies have demonstrated that IL-1b inhibitors
are able to induce complete remission of clinical mani-
festations and suppression of markers of inflammation
in the majority of patients.
Objectives
To evaluate Serum Amyloid A (SAA) level in CAPS
patients treated with anti IL-1b therapy and to correlate
its level with the response to the treatment and with the
presence of the NLRP3 mutation.
Methods
We considered all patients of CAPS Italian Register
affected by MWS or CINCA treated with IL-1b inhibitors
(Anakinra or Canakinumab). According to Lachmann
criteria a complete response to treatment was defined as
a global assessment of no or minimal disease activity by a
physician, an assessment of no or minimal rash, and a
value for both serum CRP and SAA that was within the
normal range (<0.5 mg/dL for CRP, < 6.4 mg/L for SAA).
Partial response to IL-1b inhibitors was defined as a glo-
bal assessment of no or minimal disease activity by a phy-
sician, and persistent elevated inflammatory markers
(CRP, SAA). All patients underwent genetic analysis to
identify NLRP3 mutations.
Results
26 patients (15 M, 11 F) were considered, aged 2 to 52
years (median 16.5 ys). The mean duration of follow-up
was 40 months. 18/26 patients were in treatment with
Canakinumab (5 patients ab initio and 13 after a period
with Anakinra therapy) and 8/26 patients were still tak-
ing Anakinra. 10/26 patients showed clinical remission
with normal lab tests, including SAA. 10/26 patients
presented clinical remission and normal CRP, but ele-
vated SAA, with median value of 12.8 mg/L (IQR 10.5-
16.8). 3/26 showed clinical remission but high values of
SAA and CRP; 3/26 patients presented clinical remis-
sion, normal SAA values, but high CRP values. So in
this series only 10/26 patients (38%) affected by CAPS
showed a complete response to IL-1b inhibitors. In 18/
26 patients we detected a mutation of NLRP3 gene.
Median value of SAA in the mutated patients was 6,7
(IQR 2,3-13,3), median value in no mutated patients was
6,6 (IQR 4,1-46,6).
Conclusion
In the previous studies complete response to anti-IL1
therapy fluctuates between 65% and 85%. By contrast, in
our experience anti-IL1 inhibitors induced complete
remission in only 38% of the patients because SAA
values remained high (double value respect normal
range) in half patients with no correlation between SAA
values and genetic background. We do not know the
real risk of these patients of developing amyloidosis, but
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